---
title: "Wanchen Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 855 million yuan, an increase of 917.04%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262020448.md"
description: "Wanchen Biotechnology released its Q3 2025 report, with operating revenue for the first three quarters reaching 36.562 billion yuan, a year-on-year increase of 77.37%; net profit attributable to shareholders was 855 million yuan, a year-on-year increase of 917.04%; net profit excluding non-recurring gains and losses was 806 million yuan, a year-on-year increase of 955.27%; basic earnings per share were 4.684 yuan"
datetime: "2025-10-21T09:52:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262020448.md)
  - [en](https://longbridge.com/en/news/262020448.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262020448.md)
---

# Wanchen Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 855 million yuan, an increase of 917.04%

According to the Zhitong Finance APP, Wanchen Biotechnology (300972.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 36.562 billion yuan, a year-on-year increase of 77.37%. The net profit attributable to shareholders of the listed company was 855 million yuan, a year-on-year increase of 917.04%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 806 million yuan, a year-on-year increase of 955.27%. The basic earnings per share were 4.684 yuan

### Related Stocks

- [300972.CN](https://longbridge.com/en/quote/300972.CN.md)

## Related News & Research

- [Microbiotica reports positive results for MB097 in advanced melanoma](https://longbridge.com/en/news/286740265.md)
- [Israel-based Phase 3 ocular diseases biotech Tarsier Pharma sets terms for $45 million US IPO](https://longbridge.com/en/news/286793435.md)
- [Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer](https://longbridge.com/en/news/286856224.md)
- [VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain](https://longbridge.com/en/news/286901967.md)
- [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md)